aureus strains

12 examples (0.02 sec)
  • Until 2002 such a genetic transfer was not reported for wild S. aureus strains.
  • S. aureus strains also produce enzymes and exotoxins that likely cause or increase the severity of certain diseases.
  • Northern blot experiments show that RsaOG is expressed in several S. aureus strains.
  • However, while the majority of S. aureus strains are coagulase-positive, some may be atypical in that they do not produce coagulase.
  • It has been shown to be antimycobacterial with significant antibacterial properties against multi-resistant Staphylococcus aureus strains.
  • Whole genome technologies, such as sequencing projects and microarrays, have shown an enormous variety of S. aureus strains.
  • Most human infections are caused by coagulase-positive S. aureus strains, notable for the bacteria's ability to produce coagulase, an enzyme that can clot blood.
  • This may be attributed to the persistent colonization of abnormal skin with S. aureus strains, such as is the case in persons with atopic dermatitis.
  • In 1959 Abraham reported that his N-phenylacetyl derivative of cephalosporin C was much more potent against Staphylococcus aureus strains than the parent compound.
  • S. aureus strains first infect the skin and its structures (for example, sebaceous glands, hair follicles) or invade damaged skin (cuts, abrasions).
  • Although PSM toxins are produced in all methicillin-resistant Staphylococcus aureus strains, the more virulent CA-MRSA strains are typically associated with higher production.
  • Clinical tests for detection of methicillin-resistant Staphylococcus aureus may produce false positives by detecting S. intermedius, as this species shares some phenotypic traits with methicillin-resistant S. aureus strains.